Location: Cambridge MA
Cambridge, MA-based H3 Biomedicine (https://www.h3Biomedicine.com/) is a leading company in cancer genomics driven drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million in initial funding from Eisai, plus a continued ongoing commitment to fund H3’s robust discovery pipeline and clinical programs. Now with four clinical stage anti-cancer molecules in active development, H3 is able to uniquely leverage distinct insights from cancer genomics and real-life patient data to advance its projects to clinical proof of concept and beyond. H3 embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company, to create a prolific drug discovery engine and partnership platform.
Principal Duties and Responsibilities
- Experience with resolving facilities requests
- Liaise with lab stakeholders to coordinate various projects (i.e. freezer management)
- Regularly scheduled on-call weekends to address potential facility alarms
- Support requests to assist team members with urgent issues
- Special projects completion
- Database/inventory monitoring and reconciliation
- Manual re-stocking of lab supplies
- Domestic and international shipping
- Excellent basic PM capabilities and skill sets
- Ability to prioritize task importance
- Excellent communication and interpersonal skills, coordination skills
- Sense of urgency, responsive, proactive and multitasking
- Demonstrated proficiency with Microsoft Office and Smartsheet
- Collaborative team player
- Ability to complete tasks independently
- Ability to lift 20 lbs.
- DOT/IATA, RCRA, HAZWOPER trainings a plus but not required
About H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately-held, uniquely-structured oncology discovery enterprise whose sole mission is to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.